Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA



Status:Recruiting
Conditions:Skin and Soft Tissue Infections, Infectious Disease
Therapuetic Areas:Dermatology / Plastic Surgery, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 89
Updated:4/21/2016
Start Date:February 2012
Contact:Michael Rybak, PharmD, MPH
Email:aa1592@wayne.edu
Phone:313-577-4376

Use our guide to learn which trials are right for you!

Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus

The proposed study is a prospective, open-label, randomized, multi-center trial of
ceftaroline versus vancomycin for the treatment of ABSSSI in patients documented or at risk
for MRSA. Patients admitted to the Detroit Medical Center, Henry Ford Hospital, or St. John
Medical Center in Detroit Michigan with a documented ABSSSI between April 2012 and November
2015 will be evaluated for inclusion. Patients must present with at least 3 of the following
local signs/symptoms: pain, tenderness, swelling erythema, warmth, drainage/discharge,
induration, and lymph node swelling/tenderness. Patients will be randomized 1:1 ceftaroline
or vancomycin with optional anaerobic and/or Gram-negative coverage. The assignment of study
drug will follow a randomized list that was previously generated via a computerized random
mix block generator (nQuery Advisor® 7.0) and available at each of the study sites. Patients
will be randomized to ceftaroline intravenously at 600 mg infused over 1 hour every 12 hours
for patients with normal renal function. Patients randomized to vancomycin will receive the
standard 15 mg/kg dose based on total body weight infused over 1 hour q 12 hour, dose and
interval adjusted based on creatinine clearance and via institution-specific pharmacy
protocol to target serum trough concentrations of 10-20 mg/L within the first 72 hours.
Outcomes measured in the Clinically Evaluable patient population include day two or three
size reduction (percentage) and clinical response at end of therapy or discharge.


Inclusion Criteria:

- Acute bacterial skin and skin structure infection (cellulitis, major abscess,
surgical site infection)

- Presence of MRSA or documented risk factors for MRSA (prior antibiotic use 60 days,
prior hospital exposure 180 days, skin ulcers, central venous catheter)

- Anticipating no less than two days of hospital admission

- Signed informed consent

Exclusion Criteria:

- Gas gangrene/progressive necrotizing infections

- Osteomyelitis

- Infections due to Gram-negative pathogens or other Gram-positive pathogens if S.
aureus or Streptococcus is not present

- Pathogens known at the study entry to be resistant to ceftaroline or vancomycin

- Anticipated to require non-study antibiotic active against S. aureus for another
reason

- Treatment for the current episode of ABSSSI for > 24 hours with another intravenous
anti-MRSA antibiotic

- Surgical (I & D) as definitive/curative treatment

- Presence of prosthetic hardware or invasive devices suspected to be the source of
infection but cannot be removed

- Life expectancy < 2 months

- Open burn wound > 30% total body surface area

- Pregnant or nursing mothers

- Known allergic reaction to vancomycin or ceftaroline
We found this trial at
3
sites
Detroit, Michigan 48201
Phone: 313-577-4376
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48236
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Phone: 313-916-2556
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials